Abstract
Abstract Introduction Many physiological measures derived from actigraphy including physical activity, sleep, circadian/daily rhythm, and temporal correlations have been shown to predict Alzheimer’s dementia (AD). This study aimed to combine these actigraphy-based measures to develop an integrated actigraphy biomarker (IAB) for AD and to test its link to the genetic risk for AD. Methods We analyzed data of 1107 participants (age 80.9±7.3(mean±SD)) from the Rush Memory and Aging Project who were non-demented and had actigraphy (~10 days) at baseline, and had annual cognitive assessment during the follow-up (1-15 years). 270 developed AD (mean = 7.4 years). To construct the IAB for the AD’s risk, we trained a random forest survival model, in which time to incident AD was the outcome, and inputs included 10 features derived from actigraphy data: physical activity level, 3 features for sleep (sleep duration, sleep fragmentation, activity fragmentation), 4 features for circadian rhythmicity (amplitude, acrophase, interdaily stability, and intradaily variability of 24-hr rhythms), and 2 features for temporal correlations (at timescales between 1-90 min and 120-480 min). Polygenic risk score (PRS) was calculated using 457 independent SNPs strongly associated with Alzheimer’s disease (p<0.001). Cox proportional hazard ratio models were performed with different combinations of IAB, PRS, age, sex, and education, and the concordance score (C-score) was used to evaluate model performance. Results The derived IAB was 0.6 SD larger in the AD group as compared with the controls. The IAB alone achieved a C-score = 0.61 in predicting AD, with a hazard ratio=1.5 for 1-SD increase in IAB. The IAB and PRS were not correlated (r2=0.0004, p=0.25), and both significantly contributed to the prediction (both p<=0.0001) when included in one model, giving a C-score of 0.65. C-score was 0.7 in the model using only age, sex and educations yielded, and increased to 0.74 after including IAB and PRS (both effects remained significant p<0.0001). Conclusion The integrated actigraphy biomarker may provide complementary information for early prediction and detection of AD, independent of the known demographic and genetic risk factors. Support (If Any) NIH (RF1AG064312, RF1AG059867, R01AG56352, R01AG17917, T32GM007592, and R03AG067985); The BrightFocus Foundation (A2020886S).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have